Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. (Q34528054)

2 August 2017

title

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. (English)

1 reference

2 August 2017

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

11

Gaudernack G

1 reference

2 August 2017

5

Dueland S

1 reference

2 August 2017

4

Kvalheim G

1 reference

2 August 2017

Kyte JA

1

1 reference

2 August 2017

Mu L

2

1 reference

2 August 2017

Aamdal S

3

1 reference

2 August 2017

Hauser M

6

1 reference

2 August 2017

Gullestad HP

7

1 reference

2 August 2017

Ryder T

8

1 reference

2 August 2017

Lislerud K

9

1 reference

2 August 2017

Hammerstad H

10

1 reference

2 August 2017

publication date

5 May 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

13

1 reference

2 August 2017

issue

10

1 reference

2 August 2017

page(s)

905-918

1 reference

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Do human cancers express shared protective antigens? or the necessity of remembrance of things past

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

The use of dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Autologous dendritic cell vaccines for non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Contribution of dendritic cells to stimulation of the murine syngeneic mixed leukocyte reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Manipulating dendritic cell biology for the active immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Cancer and the chemokine network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

Immunotherapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

7 January 2021

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

7 January 2021

mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

7 January 2021

Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

7 January 2021

Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

7 January 2021

Low-Level Monocyte Chemoattractant Protein-1 Stimulation of Monocytes Leads to Tumor Formation in Nontumorigenic Melanoma Cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

7 January 2021

Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700961

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700961

1 reference

2 August 2017

1 reference